Su valoración está considerada valorada de forma justa,y su reconocimiento institucional es muy alto. En los últimos 30 días, múltiples analistas han calificado a la empresa como Compra. Las acciones se mantienen sin una tendencia clara entre los niveles de soporte y resistencia, así que son adecuadas para el swing trading en un mercado lateral.
Puntuación de acciones
Información Relacionada
Ranking de la industria
140 / 207
Clasificación general
375 / 4720
Industria
Equipamiento y suministros sanitarios
Resistencia y Soporte
Sin datos
Gráfico de radar
Precio actual
Anterior
Objetivo de los analistas
Basado en un total de
2
analistas
Compra
Calificación actual
4.500
Precio objetivo
+183.02%
Espacio en ascenso
Descargo de responsabilidad: Las calificaciones de los analistas y los precios objetivo son proporcionados por LSEG con fines informativos únicamente y no constituyen asesoramiento de inversión.
Aspectos destacados de la empresa
Puntos fuertesRiesgo
HeartBeam, Inc. is a cardiac technology company. The Company is focusing on developing and commercializing higher resolution ambulatory Electrocardiogram (ECG) solutions that enable the detection and monitoring of cardiac disease both inside and outside a healthcare facility setting. The Company is engaged in the development of its proprietary and patented Vector Electrocardiography (VECG) technology platform. Its VECG is capable of developing three-dimensional vector images of cardiac electrical activity by displaying the spatial locations of ECG waveforms. It has two patented products in development, such as HeartBeam AIMI and HeartBeam AIMIGo. HeartBeam AIMI is software for acute care settings that provides a 3D comparison of baseline and symptomatic 12-lead ECG to identify a heart attack. HeartBeam AIMIGo is a credit card-sized 12-lead output ECG device coupled with a smart phone app and cloud-based diagnostic software system to facilitate remote evaluation of cardiac symptoms.
Alto crecimiento de los beneficios
Los ingresos netos de la empresa lideran el sector. Sus ingresos anuales más recientes ascienden a 50.04 USD.
Valorada de forma justa
El PE más reciente de la empresa es -2.43, en un rango percentil medio de 3 años.
Venta institucional
Las tenencias institucionales más recientes son 11.32M acciones, lo que supone una reducción del 0.14% con respecto al trimestre anterior.
HeartBeam, Inc. is a cardiac technology company. The Company is focusing on developing and commercializing higher resolution ambulatory Electrocardiogram (ECG) solutions that enable the detection and monitoring of cardiac disease both inside and outside a healthcare facility setting. The Company is engaged in the development of its proprietary and patented Vector Electrocardiography (VECG) technology platform. Its VECG is capable of developing three-dimensional vector images of cardiac electrical activity by displaying the spatial locations of ECG waveforms. It has two patented products in development, such as HeartBeam AIMI and HeartBeam AIMIGo. HeartBeam AIMI is software for acute care settings that provides a 3D comparison of baseline and symptomatic 12-lead ECG to identify a heart attack. HeartBeam AIMIGo is a credit card-sized 12-lead output ECG device coupled with a smart phone app and cloud-based diagnostic software system to facilitate remote evaluation of cardiac symptoms.